Home
Search
Study Topics
Glossary
|
|
|
|
|
|
Sponsored by: |
University Hospital of Crete |
---|---|
Information provided by: | University Hospital of Crete |
ClinicalTrials.gov Identifier: | NCT00689624 |
This study will evaluate the efficacy of FOLOFOXIRI plus Cetuximab combination in young patients with good performance status with unresectable metastatic colorectal cancer.
Condition | Intervention | Phase |
---|---|---|
Metastatic Colorectal Cancer |
Drug: Irinotecan Drug: Leukovorin Drug: Oxaliplatin Drug: 5-FLUOROURACIL Drug: Cetuximab |
Phase II |
Study Type: | Interventional |
Study Design: | Treatment, Non-Randomized, Open Label, Active Control, Single Group Assignment, Efficacy Study |
Official Title: | A Triplet Combination With Irinotecan Plus Oxaliplatin,Continuous Infusion 5-Fluorouracil And Leucovorin Plus Cetuximab As First Line Treatment In Metastatic Colorectal Cancer. A Pilot Phase II Trial |
Estimated Enrollment: | 30 |
Study Start Date: | July 2007 |
Estimated Study Completion Date: | December 2009 |
Estimated Primary Completion Date: | December 2009 (Final data collection date for primary outcome measure) |
Arms | Assigned Interventions |
---|---|
1: Experimental
FOLFOXIRI+Erbitux
|
Drug: Irinotecan
Irinotecan will be administered at a dose of 150mg/m2 as a 30 min IV infusion on day 1
Drug: Leukovorin
Leukovorin will be administered at a dose of 200mg/m2 as a 2-hour IV infusion on days 2 and 3
Drug: Oxaliplatin
Oxaliplatin will be administered on day 2 at the dose of 65mg/m2 as a 2-hours IV
Drug: 5-FLUOROURACIL
5-FLUOROURACIL at the dose of 400mg/m2 as IV bolus and then, 600mg/m2 as a 22-hour continuous IV infusion, on days 2 and 3
Drug: Cetuximab
Cetuximab will be administered at the dose of 500mg/m2 as a 2-hour infusion on day 1 at least one hour before chemotherapy
|
The combination of FOLFOXIRI plus cetuximab is reasonable safe regimen especially for patients with good performance status. The estimated benefit from the combination is greater than the possible risk, especially for the patients who will become resectable after treatment. It will be extremely interesting to evaluate the resectability rate of this specific group of patient with good performance status and unresectable disease when they are treated with all active chemotherapeutic agents and cetuximab
Ages Eligible for Study: | 18 Years to 70 Years |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
Exclusion Criteria:
Contact: Maria Kokkini | 30-28-1039-2783 | dclintrials@gmail.com |
Contact: Ioannis Athanasakis | 30-28-1039-2783 | dclintrials@gmail.com |
Greece | |
University Hospital of Crete | Recruiting |
Heraklion, Greece | |
Contact: Maria Kokkini 30-28-1039-2783 dclintrials@gmail.com | |
Contact: Ioannis Athanasakis 30-28-1039-2783 dclintrials@gmail.com | |
Sub-Investigator: Athanasios Kotsakis, MD |
Principal Investigator: | John Souglakos, MD | University Hospital of Crete |
Responsible Party: | University Hospital of Crete ( J.Sougklakos ) |
Study ID Numbers: | CT/06.21 |
Study First Received: | May 29, 2008 |
Last Updated: | November 20, 2008 |
ClinicalTrials.gov Identifier: | NCT00689624 |
Health Authority: | Greece: National Organization of Medicines |
Colorectal Cancer Cetuximab FOLFOXIRI |
Digestive System Neoplasms Gastrointestinal Diseases Cetuximab Colonic Diseases Irinotecan Leucovorin Intestinal Diseases |
Rectal Diseases Intestinal Neoplasms Oxaliplatin Digestive System Diseases Fluorouracil Gastrointestinal Neoplasms Colorectal Neoplasms |
Antimetabolites Antimetabolites, Antineoplastic Vitamin B Complex Molecular Mechanisms of Pharmacological Action Immunologic Factors Antineoplastic Agents Growth Substances Physiological Effects of Drugs Enzyme Inhibitors |
Immunosuppressive Agents Pharmacologic Actions Neoplasms Neoplasms by Site Therapeutic Uses Vitamins Micronutrients Antineoplastic Agents, Phytogenic |